Display options
Share it on

PLoS One. 2012;7(12):e52578. doi: 10.1371/journal.pone.0052578. Epub 2012 Dec 20.

Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.

PloS one

David W Chan, Winnie W Y Hui, Patty C H Cai, Michelle X Liu, Mingo M H Yung, Celia S L Mak, Thomas H Y Leung, Karen K L Chan, Hextan Y S Ngan

Affiliations

  1. Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, PR China. [email protected]

PMID: 23285101 PMCID: PMC3527599 DOI: 10.1371/journal.pone.0052578

Abstract

Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still remains unclear. In this study, we found that GRB7 (P<0.0001), ERK phosphorylation (P<0.0001) and FOXM1 (P = 0.001) were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P<0.0001), ERK phosphorylation (P<0.001) and FOXM1 (P<0.001) showed a significant stepwise increase pattern along Grade 1 to Grade 3 ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1 could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian cancer.

References

  1. J Mol Biol. 2011 Sep 23;412(3):397-411 - PubMed
  2. Cancer Res. 2011 Jul 1;71(13):4329-33 - PubMed
  3. J Biol Chem. 2002 Apr 5;277(14):11918-26 - PubMed
  4. J Cell Physiol. 2000 Jun;183(3):411-5 - PubMed
  5. Adv Anat Pathol. 2009 Sep;16(5):267-82 - PubMed
  6. Biol Chem. 2007 Dec;388(12):1257-74 - PubMed
  7. BMC Struct Biol. 2007 Sep 25;7:58 - PubMed
  8. Acta Pharmacol Sin. 2010 Mar;31(3):361-6 - PubMed
  9. Cancer Res. 1997 Jan 1;57(1):28-31 - PubMed
  10. Breast Cancer Res Treat. 2012 Jun;133(2):607-15 - PubMed
  11. Curr Cancer Drug Targets. 2010 Dec;10(8):840-8 - PubMed
  12. Expert Opin Ther Pat. 2011 Jul;21(7):1045-69 - PubMed
  13. Ann Med. 2006;38(3):200-11 - PubMed
  14. Apoptosis. 1999 Aug;4(4):271-81 - PubMed
  15. Carcinogenesis. 2008 Sep;29(9):1742-50 - PubMed
  16. J Natl Cancer Inst. 2006 Apr 5;98(7):491-8 - PubMed
  17. Am J Surg Pathol. 2004 Apr;28(4):496-504 - PubMed
  18. Presse Med. 1991 Sep 14;20(28):1320-6 - PubMed
  19. Cell Signal. 1998 Oct;10(9):613-8 - PubMed
  20. J Pathol. 2008 Jul;215(3):245-52 - PubMed
  21. Carcinogenesis. 2008 Mar;29(3):473-9 - PubMed
  22. Biochim Biophys Acta. 2012 Jan;1819(1):28-37 - PubMed
  23. Cell Cycle. 2009 Apr 15;8(8):1168-75 - PubMed
  24. Br J Cancer. 2007 May 21;96(10):1520-5 - PubMed
  25. Int J Cancer. 2004 Dec 10;112(5):747-53 - PubMed
  26. Curr Med Chem. 2007;14(5):601-23 - PubMed
  27. J Biol Chem. 1996 Nov 29;271(48):30942-9 - PubMed
  28. J Oncol. 2010;2010:932371 - PubMed
  29. PLoS One. 2012;7(1):e29902 - PubMed
  30. Eur J Gynaecol Oncol. 2010;31(2):174-80 - PubMed
  31. Mol Cancer Res. 2008 Oct;6(10):1639-48 - PubMed
  32. Gynecol Oncol. 2010 Sep;118(3):262-7 - PubMed
  33. Clin Cancer Res. 2011 Nov 1;17(21):6791-801 - PubMed
  34. Cancer Lett. 2009 Oct 8;283(2):125-34 - PubMed
  35. Oncogene. 2001 Oct 1;20(44):6315-21 - PubMed
  36. Aging (Albany NY). 2011 Mar;3(3):192-222 - PubMed
  37. Cancer Treat Rev. 2010 Apr;36(2):151-6 - PubMed
  38. Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23 - PubMed
  39. Breast Cancer Res Treat. 2011 Jun;127(3):659-69 - PubMed
  40. Bioorg Med Chem. 2011 Jan 1;19(1):693-701 - PubMed
  41. Biopolymers. 2007;88(2):174-81 - PubMed
  42. Horm Cancer. 2010 Dec;1(6):277-90 - PubMed
  43. Am J Surg Pathol. 2005 Aug;29(8):1034-41 - PubMed
  44. Oncogene. 2008 Sep 11;27(40):5315-25 - PubMed
  45. Expert Rev Mol Med. 2003 May 10;5(14):1-11 - PubMed
  46. Clin Cancer Res. 2010 May 1;16(9):2529-39 - PubMed
  47. J Mol Recognit. 2012 Jan;25(1):57-67 - PubMed
  48. Bioessays. 2010 May;32(5):412-21 - PubMed
  49. PLoS One. 2011;6(8):e23790 - PubMed

Substances

MeSH terms

Publication Types